NEOTCR-P1 adoptive cell therapy + aldesleukin

This is a **combination therapy** consisting of NEOTCR-P1, an autologous adoptive cell therapy, and aldesleukin (recombinant interleukin-2, IL-2). NEOTCR-P1 involves gene-edited T cells (CD8 and CD4) engineered to express patient-specific T cell receptors that recognize neoantigens derived from individual tumor mutations. These gene-edited T cells are manufactured via precision genome engineering and infused intravenously after lymphodepleting chemotherapy. Aldesleukin is administered subcutaneously at low doses for 7 days post-infusion to facilitate the expansion and persistence of the infused T cells. The combination is being studied primarily in patients with advanced/metastatic solid tumors (melanoma, urothelial cancer, colorectal cancer, ovarian cancer, hormone receptor-positive breast cancer, and prostate cancer) who have progressed after standard therapy. The therapy is being developed and tested in first-in-human clinical trials, and integrates **personalized immunotherapy** with cytokine support, aiming to maximize anti-tumor T cell response while maintaining safety and tolerability[1][2][3][4][6].

Brand names

NeoTCR-P1 (for the cell product)Proleukin (for aldesleukin)

Other names

Autologous neoantigen-targeted TCR-T cell therapy + aldesleukinPersonalized TCR-T therapy + IL-2